Thymectomy

Thymectomy is the surgical removal of the thymus, a small immune organ that sits behind the breastbone. In neuro-ophthalmology it comes up almost entirely in the context of myasthenia gravis, where the thymus is frequently abnormal and appears to help drive the autoimmune attack on the neuromuscular junction. Two ideas make thymectomy unusual among surgeries discussed on this site: it is sometimes done for a tumor and sometimes done to change the course of an autoimmune disease, and even when it works, the improvement is rarely quick - the payoff is measured in months to years.

Two Different Reasons to Remove the Thymus

It helps to keep the two indications separate, because they answer different questions.

The first is oncologic. A thymoma - a tumor arising in the thymus, present in a minority of people with myasthenia gravis - generally needs to be removed regardless of how the myasthenia is behaving, the same way any concerning mediastinal mass would. A thymic carcinoma or a suspicious thymic mass falls in the same category. Here, surgery is about treating the tumor; any effect on the myasthenia is a separate matter.

The second is immunologic. In many patients without a tumor (so-called nonthymomatous disease), the thymus shows hyperplasia and is thought to be a site where the autoimmune process is generated and sustained. Removing it can, over time, reduce the antibody-driven attack and ease the disease itself. This is the harder, more individualized decision, because the patient is being asked to undergo chest surgery for a benefit that is probabilistic and slow to arrive.

What the MGTX Trial Established

For decades, thymectomy was offered for nonthymomatous myasthenia largely on the strength of observational experience, which left genuine uncertainty about how much it actually helped. The MGTX trial changed that. It was a randomized controlled trial comparing thymectomy plus prednisone against prednisone alone in adults with generalized, AChR-antibody-positive, nonthymomatous myasthenia, followed over several years.

Its importance is qualitative and worth stating plainly: the thymectomy group, on average, ended up with better disease control, needed lower doses of prednisone, required less additional immunosuppression, and had fewer disease-related hospitalizations. For the first time, the benefit was demonstrated rather than inferred. That is why thymectomy is now a standard part of the conversation for the specific population the trial studied - and, just as importantly, why it is not automatically extended to populations the trial did not study.

Who Tends to Benefit, and Who Does Not

The strongest case for thymectomy mirrors the trial:

• Generalized myasthenia with AChR antibodies
• Younger and middle-aged adults, broadly those under about 60 to 65, depending on overall health
• Patients hoping to reduce a heavy long-term burden of steroids and other immunosuppressants

The benefit is far less established at the other end of the spectrum. Older patients, people with antibody-negative disease, and especially those with MuSK-antibody-positive myasthenia generally do not show the same response, and thymectomy is usually not recommended for MuSK-positive disease.

The Ocular Myasthenia Question

Whether ocular myasthenia - disease confined to the eyelids and eye movements, causing drooping lids and double vision - should be treated with thymectomy is genuinely controversial. The randomized evidence is for generalized disease, not ocular-only disease, so any benefit is extrapolated. Some specialists consider it in selected cases, partly on the theory that it might reduce the chance of progression to generalized disease, but this is an individualized judgment made with a neurologist rather than a default recommendation. Of course, ocular myasthenia in someone who also turns out to have a thymoma is a different situation - then the tumor drives the decision.

How the Operation Is Done

The surgical goal is the same regardless of route: remove the thymus, and for tumors, remove it completely with a margin. The approaches differ mainly in how invasive the access is.

• Video-assisted thoracoscopic surgery (VATS) - a minimally invasive approach through small chest incisions
• Robotic-assisted thymectomy - also minimally invasive, common at many centers
• Transsternal (open) thymectomy - dividing the breastbone, the traditional approach and still preferred for large or invasive tumors
• Transcervical thymectomy - through a small neck incision, used in selected cases

Minimally invasive approaches generally mean less pain and a quicker recovery, while an open sternotomy gives the widest exposure when a tumor demands it. Surgery typically takes a few hours, the hospital stay is often a few days, and chest soreness and fatigue ease over the following weeks.

A Benefit Measured in Months and Years

The single most important expectation to set is timing. Unlike pyridostigmine, which works within an hour, or rescue treatments like IVIG and plasmapheresis that act over days, thymectomy works on the timescale of the immune system remodeling itself. Improvement typically emerges gradually over the first year and can keep building for two to three years. Because of that lag, patients continue their myasthenia medications after surgery, and dose reductions are made cautiously by neurology as the disease allows. The right way to judge thymectomy is not the week after surgery but the years that follow.

Risks Worth Knowing

Beyond the perioperative myasthenia risk above, thymectomy carries the usual risks of major chest surgery: bleeding, infection, and the standard risks of anesthesia. Injury to the phrenic nerve, which controls the diaphragm, is uncommon but consequential because it affects breathing. Pneumonia and other respiratory complications can occur, particularly in patients whose breathing muscles are already affected by their disease. A thoracic surgeon and neurologist coordinate care to keep these risks as low as possible.

Frequently Asked Questions

If my myasthenia is well controlled on medication, do I still need a thymectomy?

Not necessarily. If you have a thymoma, the tumor itself needs to come out. But if you have nonthymomatous disease that is well controlled, thymectomy is a shared decision weighing the slow, probable long-term benefit against the cost of surgery. Some patients choose it to reduce future medication burden; others, already stable, reasonably decide against it.

How soon will I feel better after surgery?

Plan for patience rather than a quick change. Most of the benefit unfolds over months, and improvement can continue for two to three years. Many patients feel about the same in the first weeks, which is expected and not a sign the surgery failed.

Will I be able to stop my myasthenia medications afterward?

Sometimes doses can be lowered over time, and a minority of patients achieve remission, but this is gradual and guided by your neurologist. Do not stop or reduce medications on your own - changes are made slowly as the disease eases.

Is the minimally invasive approach as effective as open surgery?

For appropriate candidates, minimally invasive thymectomy aims to remove the same tissue with less pain and faster recovery. The open approach is chosen when a tumor is large or invasive and complete removal requires wider exposure. Your surgeon selects the route based on your anatomy and imaging.